Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Kotasek, Dusan
Nagrial, Adnan
Lumba, Sumit
Tebbutt, Niall C.
George, Thomas J.
Smith, Sheri Lynn
Gagnon, Suzanne
Cullen, Michael T.
Walker, Michael J.
机构：
[1] Univ Adelaide, Adelaide, SA, Australia
[2] Blacktown Hosp, Canc & Haematol Ctr, Blacktown, NSW, Australia
[3] John Flynn Private Hosp, Canc & Haematol Ctr, Tugun, Qld, Australia
[4] Heidelberg Repatriat Hosp, AfA A A, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Vic, Australia
[5] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[6] Courante Oncol, Excelsior, MN USA
[7] Sun BioPharma Inc, Jamestown, RI USA
[8] Sun BioPharma Inc, Waconia, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
710
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [42] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Y.
    Karhan, O.
    Urakci, Z.
    Mecidova, N.
    Araz, M.
    Sakin, A.
    Ercek, B. M.
    Urun, M.
    Urvay, S.
    Aykan, M. B.
    Kocak, S.
    Arici, M. O.
    Avci, N.
    Alkan, A.
    Ozcelik, M.
    Aldemir, M. N.
    Ergun, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S930 - S930
  • [43] Phase III study (daNIS-2) of the antieTGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma
    O'Reilly, E.
    Golan, T.
    Ikeda, M.
    Milella, M.
    Taieb, J.
    Wainberg, Z.
    Wang, L.
    Gyambibi, N.
    Lopez, E.
    Xu, K.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S254 - S254
  • [44] Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer
    Kokkali, S.
    Drizou, M.
    Tripodaki, E.
    Stefanou, D.
    Magou, E.
    Zylis, D.
    Kapiris, M.
    Nasi, D.
    Georganta, C.
    Ardavanis, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    Borazanci, Erkut Hasan
    Bahary, Nathan
    Oberstein, Paul Eliezer
    Chung, Vincent
    Skeel, Roland T.
    Chiorean, E. Gabriela
    Greenstein, Andrew E.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Mann, Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
  • [49] Third -line re -treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel
    Das, A.
    Dean, A.
    McNulty, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] First-line Nab-paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer from Routine Clinical Practice
    Vogel, Arndt
    Pelzer, Uwe
    Salah-Eddin, Al-Batran
    Koester, Wolf
    IN VIVO, 2014, 28 (06): : 1135 - 1140
12345